Evidence map›Paper›PMID 32094077›Full record

ArticleRespiratory investigation2020

Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells.

Mutsuo Yamaya, Hidekazu Nishimura, Xue Deng, Mitsuru Sugawara, Oshi Watanabe, Kazuhiro Nomura, Yoshitaka Shimotai, Haruki Momma, Masakazu Ichinose, Tetsuaki Kawase

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed, 9 pooled it
34.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 9 syntheses or guidelines pooled it, 259 citations in OpenAlex.

  1. Pooled it
  2. Inhaled corticosteroids' effect on COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2023
    Pooled it
  3. Risk of serious COVID-19 outcomes among adults and children with moderate-to-severe asthma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  4. Inhaled corticosteroids for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  5. Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Bronchial Asthma and COVID-19: Etiology, Pathological Triggers, and Therapeutic Considerations.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024
    Review
  20. Article

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Mutsuo YamayaDepartment of Advanced Preventive Medicine for Infectious Disease, Tohoku University School of Medicine, Sendai, Japan. Electronic address: myamaya@med.tohoku.ac.jp.
Hidekazu NishimuraVirus Research Center, Clinical Research Division, Sendai Medical Center, Sendai, Japan. Electronic address: hide-nishimura@mte.biglobe.ne.jp.
Xue DengDepartment of Advanced Preventive Medicine for Infectious Disease, Tohoku University School of Medicine, Sendai, Japan. Electronic address: dengxuexue@hotmail.com.
Mitsuru SugawaraDepartment of Otolaryngology, Tohoku Kosai Hospital, Sendai, Japan. Electronic address: mi-sugawara@tohokukosai.com.
Oshi WatanabeVirus Research Center, Clinical Research Division, Sendai Medical Center, Sendai, Japan. Electronic address: watanabe.oshi.zr@mail.hosp.go.jp.
Kazuhiro NomuraDepartment of Otolaryngology-Head and Neck Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: kazuhiroe@gmail.com.
Yoshitaka ShimotaiDepartment of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan. Electronic address: yoshimo@med.id.yamagata-u.ac.jp.
Haruki MommaDepartment of Medicine and Science in Sports and Exercise, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: harupiyo326@hotmail.com.
Masakazu IchinoseDepartment of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Electronic address: ichinose@rm.med.tohoku.ac.jp.
Tetsuaki KawaseLaboratory of Rehabilitative Auditory Science, Tohoku University Graduate School of Biomedical Engineering, Sendai, Japan. Electronic address: kawase@orl.med.tohoku.ac.jp.
Tohoku University · JPSendai Medical Center · JPKKR Tohoku Kosai Hospital · JPYamagata University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronavirus 229E (HCoV-229E), one of the causes of the common cold, exacerbates chronic obstructive pulmonary disease (COPD) and bronchial asthma. Long-acting muscarinic antagonists and β

methodsPrimary human nasal (HNE) and tracheal (HTE) epithelial cell cultures were infected with HCoV-229E.

resultsPretreatment of HNE and HTE cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E receptor CD13, the number and fluorescence intensity of acidic endosomes where HCoV-229E RNA enters the cytoplasm, and the infection-induced production of cytokines, including IL-6, IL-8, and IFN-β. Treatment of the cells with the CD13 inhibitor 2'2'-dipyridyl decreased viral titers. Pretreatment of the cells with a combination of three drugs (glycopyrronium, formoterol, and budesonide) exerted additive inhibitory effects on viral titers and cytokine production. Pretreatment of HNE cells with glycopyrronium or formoterol reduced the susceptibility to infection, and pretreatment with the three drugs inhibited activation of nuclear factor-kappa B p50 and p65 proteins. Pretreatment with formoterol increased cAMP levels and treatment with cAMP decreased viral titers, CD13 expression, and the fluorescence intensity of acidic endosomes.

conclusionsThese findings suggest that glycopyrronium, formoterol, and a combination of glycopyrronium, formoterol, and budesonide inhibit HCoV-229E replication partly by inhibiting receptor expression and/or endosomal function and that these drugs modulate infection-induced inflammation in the airway.

Indexed as

Adrenergic beta-2 Receptor AgonistsBudesonideCD13 AntigensCells, CulturedCoronavirusCytokinesEpithelial CellsFormoterol FumarateGlycopyrrolateHumansMuscarinic AntagonistsNasal MucosaTracheaVirus ReplicationAdrenergic beta-2 Receptor AgonistsBudesonideCD13 AntigensCytokinesFormoterol FumarateGlycopyrrolateMuscarinic AntagonistsAirway epithelial cellsCD13HCoV-229ELong-acting muscarinic antagonistLong-acting β(2) agonist

Identifiers

PMID32094077
PMCPMC7102607
OpenAlexW3007109299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.